Truist Securities Maintains Buy on Medline, Lowers Price Target to $47
Benzinga Newsdesk 2 months ago
Analyst RatingsNewsPrice Target
Truist Securities analyst Jailendra Singh maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $56 to $47.
Truist Securities analyst Jailendra Singh maintains Medline (NASDAQ:MDLN) with a Buy and lowers the price target from $56 to $47.